Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab
Helsinki, Finland, 13th July 2021 – Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has submitted a clinical trial application (CTA) to the German Regulatory Agency, The Paul Ehrlich Institute (PEI) for a Phase I, first-in-human trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus 1) in three tumor types.
